Hyperhaemolytic transfusion reaction in two ß-thalassaemia major patients: The role of eculizumab.
J Clin Pharm Ther
; 47(3): 411-414, 2022 Mar.
Article
em En
| MEDLINE
| ID: mdl-34397109
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Hyperhaemolytic transfusion reactions are rare life-threatening events predominantly affecting patients with haemoglobinopathies. We report two cases in ß-thalassaemia major patients on chronic transfusion therapy and highlight the role of eculizumab in its management. CASESUMMARY:
Patient 1 presented with intravascular haemolysis on day 7 (D7) post-transfusion and responded to treatment with corticosteroids and intravenous immunoglobulin. However, patient 2 presented with severe symptomatic anaemia (D4 post-transfusion) unresponsive to the aforementioned measures. Eculizumab administration led to resolution of the hyperhaemolysis. WHAT IS NEW ANDCONCLUSION:
We report the successful management of hyperhaemolysis with eculizumab in a ß-thalassemia major patient.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Talassemia beta
/
Reação Transfusional
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article